Introduction {#Sec1}
============

Nitric oxide synthase (NOS) catalyzes the generation of nitric oxide (NO), an important signaling molecule that mediates many of its biological effects by activating the enzyme guanylyl cyclase, thereby increasing cyclic GMP synthesis (Murad [@CR9]). Besides its important role in cardiovascular control, NO has been suggested to play a role in development (Lee and Juchau [@CR8]). NO has been demonstrated to be present in the neural tube of chick embryos at the time of neurulation (Traister et al. [@CR19]) and regulates the balance between mitosis and programmed cell death (Plachta et al. [@CR11]). Other studies show that NO can inhibit methionine synthase (MTR) enzyme activity, thereby interfering with homocysteine remethylation (Danishpajooh et al. [@CR3]) and proper neurulation (Nachmany et al. [@CR10]; Weil et al. [@CR22]).

The 894G\>T single nucleotide polymorphism (SNP) in the endothelial-derived nitric oxide synthase (*NOS3*) gene, identified by Hingorani et al. ([@CR7]), was shown to be associated with elevated plasma homocysteine levels in nonsmokers with low serum folate concentrations (Brown et al. [@CR2]). More recently, it was demonstrated that the *NOS3* 894GT genotype is an embryonic risk factor for spina bifida (OR 1.63, 95%CI 1.09--2.42) (Brown et al. [@CR1]).

In this study, we examined the relation between the *NOS3* 894G\>T SNP and spina bifida risk in both mothers and children using a case-control design and a transmission disequilibrium test (TDT). An effect of the *NOS3* 894G\>T SNP on plasma homocysteine or plasma folate concentration was examined as well as possible interactions between the *NOS3* 894G\>T SNP and the *MTHFR* 677C\>T SNP, elevated plasma homocysteine, and decreased plasma folate concentrations.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

The study population has been described in detail before (van der Linden et al. [@CR21]). Briefly, the study population was recruited in collaboration with the BOSK and was extended by a group from the Pediatric Neurology Department of the Radboud University Nijmegen Medical Center. The study group included 109 spina bifida patients (61 girls and 48 boys, mean age 16.4 ± 11.3), their mothers (*n* = 121, mean age 42.9 ± 10.9) and fathers (*n* = 103, mean age 44.9 ± 10.2).

The control group consisted of 500 volunteers recruited from a general practice in The Hague (den Heijer et al. [@CR4]). In the present study we only included the 292 women from this control group (mean age 50.6 ± 13.5). The pediatric control group included 234 children (119 girls and 115 boys, mean age 8.4 ± 6.4) (van Beynum et al. [@CR20]). The children of secondary school age were healthy volunteers, and the younger children were, for ethical reasons, recruited in a hospital setting. The local medical ethics committee approved the study.

For the present study, DNA of 102 spina bifida patients, 116 mothers, 101 fathers, 265 control women and 211 pediatric controls was available for genotyping.

Biochemical determinations {#Sec4}
--------------------------

Plasma total homocysteine concentration was measured in EDTA plasma by HPLC and fluorescence detection, as previously described by te Poele-Pothoff et al. ([@CR16]).

Plasma folate concentration was determined using the Dualcount Solid Phase Boil Radio assay (Diagnostic Product Corporation, Los Angeles, CA).

PCR amplification and genotype determination {#Sec5}
--------------------------------------------

*NOS3* 894G\>T genotyping was performed according to Hingorani et al. ([@CR7]). Primer annealing took place at a temperature of 58°C. The PCR product of 206 bp was cut with the restriction enzyme *Mbo*I, which cuts the T allele in fragments of 119 and 87 bp.

Statistical analyses {#Sec6}
--------------------

### Case-control study {#Sec7}

Odds ratios (ORs) and their 95% confidence intervals (95%CI) were calculated by means of logistic regression analysis.

The effect of the *NOS3* 894G\>T SNP on plasma homocysteine and plasma folate concentration was studied by means of linear regression analysis. Since the distributions of plasma homocysteine and plasma folate concentrations are positively skewed, these variables were logarithmically transformed prior to linear regression analysis.

Deviation from Hardy--Weinberg equilibrium was calculated to assess the accuracy of the genotyping assay.

The power of the case-control study was calculated using the Genetic Power Calculator (Purcell et al. [@CR12]). All tests were performed using SPSS software package version 12.0.1. Statistical significance was accepted at a two-tailed *P* \< 0.05 or 95%CI of an odds ratio that did not include 1.0.

### Transmission disequilibrium test {#Sec8}

The relation between the *NOS3* 894G\>T genotype of the spina bifida patients and spina bifida risk was assessed by evaluating the transmission of alleles from heterozygous parents to their affected offspring using the TDT, a family-based association test (Spielman et al. [@CR14]). The power of the TDT was calculated using the Genetic Power Calculator (Purcell et al. [@CR12]).

Results {#Sec9}
=======

Case-control study {#Sec10}
------------------

The *NOS3* 894G\>T genotype could be determined in 115 mothers of a spina bifida affected child and in 259 female controls. Genotype distribution did not differ from that expected under Hardy--Weinberg equilibrium (*P* = 0.83), and the power to detect a twofold increase in maternal spina bifida risk was 59%. Table [1](#Tab1){ref-type="table"} demonstrates that neither the *NOS3* 894GT genotype nor the *NOS3* 894TT genotype increased maternal spina bifida risk relative to the *NOS3* 894GG genotype. Since the effect of the *NOS3* 894GT genotype and the *NOS3* 894TT genotype on spina bifida risk was the same relative to the *NOS3* 894GG genotype, the *NOS3* 894GT and TT genotypes were combined to increase power, which resulted in a nonsignificant 36% increased risk of having a spina bifida affected child relative to the *NOS3* 894GG genotype (OR 1.36, 95%CI 0.87--2.11). The *NOS3* 894G\>T SNP was not associated with plasma homocysteine or plasma folate concentrations in mothers and female controls (data not shown). Table 1The *NOS3* 894G\>T genotype distribution and unadjusted ORs in mothers of a spina bifida affected child and female controls*NOS3* 894G\>TMothers (%)Female controls (%)OR (95%CI)GG49 (42.6)130 (50.2)1^a^GT53 (46.1)106 (40.9)1.33 (0.83--2.11)TT13 (11.3)23 (8.9)1.50 (0.71--3.19)^a^Reference group

In 95 spina bifida patients and 207 pediatric controls, *NOS3* 894G\>T genotyping was performed successfully. The *NOS3* 894G\>T genotype distribution did not differ from that expected under Hardy--Weinberg equilibrium (*P* = 0.76), and the power of the study was 51%. The *NOS3* 894GT genotype increased spina bifida risk in children whereas the *NOS3* 894TT genotype did not (Table [2](#Tab2){ref-type="table"}). Combining the *NOS3* 894GT and 894TT genotypes resulted in a 66% increase in spina bifida risk relative to the *NOS3* 894GG genotype (OR 1.66, 95%CI 1.02--2.72). In the pediatric controls, the *NOS3* 894GT and 894TT genotypes were associated with increased plasma homocysteine concentrations relative to the *NOS3* 894GG genotype (14.7% increase, 95%CI 4.2--26.2% and 23.5% increase, 95%CI 3.9--46.8%, respectively). There was no association between the *NOS3* 894G\>T SNP and plasma folate concentration in children (data not shown). Table 2The *NOS3* 894G\>T genotype distribution and unadjusted ORs in spina bifida patients and pediatric controls*NOS3* 894G\>TSB patients (%)Pediatric controls (%)OR (95%CI)GG39 (41.1)111 (53.6)1^a^GT46 (48.4)80 (38.6)1.64 (0.98--2.74)TT10 (10.5)16 (7.7)1.78 (0.75--4.25)^a^Reference group

Transmission disequilibrium test {#Sec11}
--------------------------------

In this study there were 75 complete mother--father--child triads, and the power to detect a twofold increase in spina bifida risk was 32%. In 36 out of 70 informative transmissions (51.4%), the *NOS3* 894T allele was transmitted to the child, which resulted in a *Χ*^2^ of 0.06 (*P* = 0.81).

Gene-gene interaction {#Sec12}
---------------------

Data on both the *NOS3* 894G\>T genotype and the *MTHFR* 677C\>T genotype were present for 110 mothers of a spina bifida affected child and 259 control women. Since the *MTHFR* 677CT genotype did not increase spina bifida risk relative to the *MTHFR* 677CC genotype, we decided to combine the *MTHFR* 677CC and CT genotypes to increase power. In combination with the *MTHFR* 677TT genotype, the *NOS3* 894GT/TT genotype increased the risk of having spina bifida affected offspring 4.5 times relative to the *NOS3* 894GG genotype combined with the *MTHFR* 677CC/CT genotype (OR 4.52, 95%CI 1.55--13.22) (Table [3](#Tab3){ref-type="table"}). Table 3Maternal spina bifida risk for the combination of the *NOS3* 894G\>T SNP and the *MTHFR* 677C\>T SNP*NOS3* 894G\>T*MTHFR* 677C\>TMothers (%)Female controls (%)OR (95%CI)GGCC/CT42 (38.2)114 (44.0)1^a^GGTT6 (5.5)16 (6.2)1.02 (0.37--2.77)GT/TTCC/CT52 (47.3)123 (47.5)1.15 (0.71--1.85)GT/TTTT10 (9.1)6 (2.3)4.52 (1.55--13.22)^a^Reference group

In children, there was no interaction between the *NOS3* 894GT/TT genotype and the *MTHFR* 677TT genotype (OR 1.23, 95%CI 0.31--4.91) (data not shown).

Gene-metabolite interactions {#Sec13}
----------------------------

Since the *MTHFR* 677C\>T SNP is a genetic determinant of plasma folate and plasma homocysteine concentrations, possible interactions between the *NOS3* 894G\>T SNP and these metabolites were examined in mothers. In combination with decreased plasma folate concentrations (\<8.52 nmol/L), the *NOS3* 894GT/TT genotype did not increase maternal spina bifida risk relative to the *NOS3* 894GG genotype in combination with normal plasma folate concentrations (≥8.52 nmol/L) (OR 1.14, 95%CI 0.49--2.67) (data not shown). The risk of having spina bifida affected offspring increased to 3.4-fold when the *NOS3* 894GT/TT genotype was present in combination with elevated plasma homocysteine concentrations (≥12.56 μmol/L) (OR 3.38, 95%CI 1.46--7.84) (Table [4](#Tab4){ref-type="table"}). Table 4Maternal spina bifida risk for the combination of the *NOS3* 894G\>T SNP and elevated plasma homocysteine concentration, adjusted for age*NOS3* 894G\>TPlasma Hcy conc (μmol/L)^a^Mothers (%)Female controls (%)OR (95%CI)GG\<12.5642 (36.8)100 (38.6)1^b^GG≥12.567 (6.1)30 (11.6)0.66 (0.26--1.65)GT/TT\<12.5647 (41.2)108 (41.7)1.17 (0.69--1.96)GT/TT≥12.5618 (15.8)21 (8.1)3.38 (1.46--7.84)^a^The 80th percentile of the control plasma homocysteine distribution was used to define elevated plasma homocysteine concentrations^b^Reference group

Discussion {#Sec14}
==========

In this study, the *NOS3* 894TT genotype did not significantly increase spina bifida risk, and the TDT demonstrated no preferential transmission of the *NOS3* 894T allele. However, in combination with the *MTHFR* 677TT genotype or elevated plasma homocysteine concentrations, the *NOS3* 894GT/TT genotype increased maternal spina bifida risk 4.5- and 3.4-fold, respectively.

Using a likelihood ratio test (LRT) for both proband and mother trios, Brown et al. ([@CR1]) demonstrated the *NOS3* 894GT genotype, but not the *NOS3* 894TT genotype, to be an embryonic risk factor for spina bifida (OR 1.63, 95%CI 1.09--2.42). Data from our case-control study might be in line with this observation of Brown et al. ([@CR1]); however, based on the effect of the heterozygous *NOS3* 894GT genotype on spina bifida risk, a larger effect of the *NOS3* 894TT genotype on spina bifida risk would be expected. The observation that the *NOS3* 894GT genotype increases spina bifida risk and the *NOS3* 894TT genotype does not could be explained as a chance finding, but could also be the result of lack of power, as also suggested by Brown et al. ([@CR1]).

Despite the small numbers on which the analyses are based, the possible interactions between the *NOS3* 894GT/TT genotype and the *MTHFR* 677TT genotype or elevated plasma homocysteine concentrations are interesting and may suggest a role for NOS3 uncoupling or S-nitrosation. The *NOS3* 894G\>T SNP (Glu298Asp) has been suggested to impair NOS3 protein function and/or activity resulting in decreased NO production (Sofowora et al. [@CR13]; Tesauro et al. [@CR17]), although results are contradictory (Fairchild et al. [@CR5]). Elevated homocysteine concentrations have been demonstrated to switch the NOS3 enzyme to an uncoupled state directed to the synthesis of reactive oxygen species (ROS) rather than NO synthesis (Topal et al. [@CR18]). The combination of the *NOS3* 894GT/TT genotype and elevated plasma homocysteine concentrations may lead to such a decrease in NO levels that neurulation is hampered. NO can also react with homocysteine to form *S*-nitrosothiols, thereby modulating homocysteine availability (Stamler et al. [@CR15]). As previously suggested by our group (Heil et al. [@CR6]), decreased NO levels may result in decreased *S*-nitrosothiol formation, resulting in less capturing of homocysteine into *S*-nitrosoHcy. The subsequent increase in plasma homocysteine concentrations might influence proper neural tube closure, especially when plasma homocysteine concentrations are already high.

The results of our study suggest that the *NOS3* 894G\>T SNP is a spina bifida risk factor in the mother and not in the child. Our results furthermore indicate a role for the homocysteine metabolism in the detrimental effects asserted by the *NOS3* 894G\>T SNP. More studies on the association between the *NOS3* 894G\>T SNP and spina bifida in larger populations are warranted.
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